Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=6&sort=-approved
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-approved", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-approved", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=7&sort=-approved", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-approved" }, "data": [ { "type": "Grant", "id": "9728", "attributes": { "award_id": "1R01HD107753-01", "title": "Maternal COVID-19 Vaccination and Lactation Outcomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 8894, "first_name": "Zhaoxia", "last_name": "Ren", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-07-01", "end_date": "2025-04-30", "award_amount": 618968, "principal_investigator": { "id": 25567, "first_name": "Kristin", "last_name": "Palmsten", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1861, "ror": "", "name": "HEALTHPARTNERS INSTITUTE", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The efficacy of coronavirus disease (COVID-19) vaccines available in the US is up to 95% against symptomatic COVID-19. However, pregnant and lactating individuals were excluded from initial clinical trials. COVID-19 vaccine trials are now underway in pregnant women in their second or third trimester but are not expected to conclude until 2022 or 2023, and evaluation of lactation outcomes is not planned. COVID-19 vaccines are highly effective, and mounting evidence suggests immunogenic protection for breastfed infants of mothers receiving COVID-19 vaccines. To date, there are no published studies on COVID-19 vaccine safety during pregnancy or lactation for breastfed infants, milk production and excretion, or other lactation-related outcomes. This lack of safety data threatens to undermine vaccination efforts in pregnant and lactating women. Traditional data sources used for post-licensure surveillance have limited relevance for lactation outcomes . Spontaneous reporting systems suffer from reporting bias due to their voluntary nature; their lack of a denominator of vaccinated lactating women precludes risk estimates. The CDC's V-Safe program, smart phone-based monitoring for vaccine side effects, does not capture lactation status. Ongoing health care claims-based surveillance studies also do not routinely capture lactation. Observational studies enrolling COVID-vaccinated lactating women rely primarily on self-reported outcomes and have limited generalizability. To address the need for comprehensive safety data, we propose a novel study of antenatal and postpartum COVID-19 vaccination and lactation-related outcomes in mother-infant pairs, including more than 11,000 breastfeeding dyads. We will use electronic health record data linked with state immunization data across four large health systems to study infant growth, infant heath care utilization, maternal mastitis, and breastfeeding status up to 7 months after delivery following maternal COVID-19 vaccination. Also, we will explore acute infant outcomes and abnormal infant developmental screens following maternal COVID-19 vaccination. We are uniquely positioned to overcome lack of information on lactation status and reporting and volunteer bias using routinely collected information on breastfeeding at well-child visits for a defined population. We will apply rigorous epidemiologic methods, including propensity score adjustment, to address confounding. With a focus on lactation, our study will complement other studies of COVID-19 vaccination in pregnancy and studies collecting milk samples from COVID-19-vaccinated volunteers. It will provide essential and currently unavailable evidence regarding lactation-related outcomes following perinatal COVID-19 vaccination. Findings supporting safety can reduce vaccine hesitancy, whereas results identifying a potential harm will be important for informing patient decision making. Furthermore, the novel approach and methods for studying lactation related outcomes developed through the proposed study can be adapted to efficiently evaluate the safety of drugs and vaccines currently recommended or being investigated for use in pregnant or postpartum women.", "keywords": [ "Acute", "Address", "Age-Months", "Biological", "Body Composition", "Breast Feeding", "Breastfed infant", "COVID-19", "COVID-19 impact", "COVID-19 vaccination", "COVID-19 vaccine", "Caring", "Cellular Phone", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Clinical Trials", "Complement", "Cytomegalovirus", "Data", "Data Sources", "Decision Making", "Dehydration", "Development", "Discipline of obstetrics", "Dose", "Electronic Health Record", "Enrollment", "Epidemiologic Methods", "Evaluation", "Excretory function", "Fatigue", "Fever", "Frequencies", "Growth", "Guidelines", "Health system", "Healthcare", "Human", "Human Milk", "Icterus", "Immunization", "Individual", "Infant", "Inflammatory Response", "Influenza", "Lactation", "Licensure", "Link", "Malaise", "Methods", "Milk", "Monitor", "Mothers", "Nature", "Observational Study", "Outcome", "Patient Self-Report", "Patients", "Perinatal", "Population", "Positioning Attribute", "Postpartum Period", "Postpartum Women", "Pregnancy", "Pregnant Women", "Professional Organizations", "Publishing", "RNA vaccine", "Reporting", "Respiratory syncytial virus", "Risk", "Risk Estimate", "Safety", "Sampling", "Screening Result", "Second Pregnancy Trimester", "Surveys", "System", "Third Pregnancy Trimester", "Vaccinated", "Vaccination", "Vaccines", "Viral Proteins", "Viral Vector", "Well Child Visits", "Woman", "antenatal", "base", "coronavirus disease", "cytokine", "health care delivery", "health care service utilization", "immunogenic", "infant outcome", "mastitis", "medication safety", "milk production", "novel", "novel strategies", "perinatal period", "pregnant", "programs", "side effect", "surveillance study", "symptomatic COVID-19", "vaccine access", "vaccine hesitancy", "vaccine safety", "vaccine trial", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "16128", "attributes": { "award_id": "1R01AI190919-01A1", "title": "Vectored Immunoprophylaxis of SARS-CoV-2 with receptor decoys", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32536, "first_name": "DIPANWITA", "last_name": "BASU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-05-19", "end_date": "2031-04-30", "award_amount": 836484, "principal_investigator": { "id": 44610, "first_name": "Nathaniel R.", "last_name": "Landau", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 832, "ror": "", "name": "NEW YORK UNIVERSITY SCHOOL OF MEDICINE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Monoclonal antibody therapy for severe COVID-19 and for prophylaxis in immunocompromised individuals was initially of great value but was sidelined by the rapid emergence of virus variants with mutations in the spike gene that rendered the antibodies ineffective. Receptor decoys offer a means to overcome this problem. Because the viral spike protein needs to conserve its high affinity for ACE2, there is a high genetic barrier for the virus to escape from neutralization by the decoy. The project will develop vectored immunoprophylaxis (VIP) in which high affinity ACE2 receptor decoys will be expressed by adeno-associated virus (AAV) and lentiviral viral vectors. These will be used to protect against and to treat SARS-CoV-2 infection. The decoys consist of the extracellular domain of ACE-2 fused to a truncated immunoglobulin heavy chain Fc region. The “microbody” neutralizes the virus by binding to the viral spike protein and will be active against all variants. Because the decoys are composed entirely of human-derived protein components, they will be well-tolerated by the human immune system. The decoys will be optimized to increase their affinity for the spike protein and will be produced with Fc regions that alter their tissue localization, half-life, antiviral activity and antibody effector functions. The decoys will be tested as recombinant protein for prophylactic and therapeutic efficacy in ACE2 transgenic mouse and hamster models against a panel of SARS-CoV-2 variants. Tissue localization and half-life of vector-expressed decoy proteins will be determined by live-imaging of decoy–luciferase fusions. Long-term protection against infection will be established with decoy-expressing AAV and lentiviral vectors in mice and hamsters by intranasal instillation and intramuscular injection. The animals will then be challenged with live virus up to a year post- administration. Serum and lung concentrations of the decoy will be measured and the host antibody response to the decoy protein will be tested. An optimized decoy will be designed based on the findings obtained with modified decoy proteins and its effectiveness will be studied in rhesus macaques, a model that closely resembles humans. The decoy approach will be valuable for rapidly establishing long-term protection, and will be of value to immunocompromised individuals for whom vaccination is less effective. The approach offers an off-the-shelf means with which to rapidly protect the population in the event of a novel zoonotic coronavirus pandemic. The lessons learned will be broadly applicable to other viruses for which a decoy receptor can be generated.", "keywords": [ "2019-nCoV", "ACE2", "Acquired Immunodeficiency Syndrome", "Aerosols", "Affect", "Affinity", "Amino Acids", "Animal Model", "Animals", "Antibodies", "Antibody Response", "Binding", "Binding Proteins", "COVID-19 treatment", "COVID-19 vaccination", "Cell Surface Receptors", "Data", "Death Rate", "Dependovirus", "Development", "Disease", "Effectiveness", "Epitopes", "Event", "Evolution", "Exposure to", "Extracellular Domain", "Future", "Gene Transduction Agent", "Generations", "Genes", "Genetic", "Genetic Diseases", "Half-Life", "Hamsters", "Heavy-Chain Immunoglobulins", "Human", "Image", "Immune response", "Immune system", "Immunization Programs", "Immunocompromised Host", "Individual", "Infection", "Intramuscular", "Intramuscular Injections", "Investments", "Length", "Lentivirus Vector", "Luciferases", "Lung", "Macaca", "Macaca mulatta", "Malignant Neoplasms", "Measures", "Modeling", "Monoclonal Antibodies", "Monoclonal Antibody Therapy", "Mus", "Mutation", "Pathogenicity", "Pharmaceutical Preparations", "Physiological", "Population", "Predisposition", "Production", "Prophylactic treatment", "Proteins", "Recombinant Proteins", "Recombinants", "Resistance", "Respiratory System", "SARS-CoV-2 infection", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Serotyping", "Serum", "Testing", "Therapeutic", "Therapeutic Effect", "Tissues", "Transgenic Mice", "Transplantation", "Treatment Efficacy", "Update", "Vaccination", "Vaccines", "Variant", "Viral", "Viral Antibodies", "Viral Physiology", "Viral Vector", "Viral load measurement", "Virus", "Virus Diseases", "Virus Receptors", "Virus Replication", "acute COVID-19", "acute infection", "adeno-associated viral vector", "compare effectiveness", "coronavirus pandemic", "delivery vehicle", "design", "effectiveness evaluation", "emerging virus", "future pandemic", "hospitalization rates", "immunoprophylaxis", "microbody", "nonhuman primate", "nonhuman primate models", "novel", "pandemic virus", "prevent", "prophylactic", "receptor", "severe COVID-19", "success", "transmission process", "vaccine immunogenicity", "vector", "weapons", "zoonotic coronavirus" ], "approved": true } }, { "type": "Grant", "id": "7936", "attributes": { "award_id": "1R43HL164325-01", "title": "IVOS Medical: Intubation, optimized.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 6344, "first_name": "Lora A.", "last_name": "Reineck", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-04-01", "end_date": "2022-09-30", "award_amount": 247334, "principal_investigator": { "id": 23805, "first_name": "Gabriel", "last_name": "Punsalan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1644, "ror": "", "name": "IVOS MEDICAL LLC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23806, "first_name": "WAYLAN", "last_name": "WONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1644, "ror": "", "name": "IVOS MEDICAL LLC", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Endotracheal intubation (ETI) is a frequently used life-saving procedure performed daily. In the US alone, 15 million operating room intubations and 650,000 out-of-operating room intubations are performed annually. At the initial outbreak of the SARS-Cov-2 pandemic of 2020, more than 70% of critically ill patients were intubated and with new mutations, the increase in emergent intubation is only going to continue. Despite its frequency, ETI is a high-risk procedure, with significant rates of respiratory complications, hemodynamic instability, and cardiac arrest. Developed in the early 2000s, the video laryngoscope (VL) was created to assist with difficult intubations vs the traditional practice by direct laryngoscopy (DL). This new method of intubation works by means of a video camera on the distal end of the laryngoscope blade which is inserted into the mouth and provides an indirect view of the vocal cords on a separate monitor. This widely-used tool for visualizing the airway has garnered more acceptance as a first line tool for intubation in an emergent setting.The current problem with intubation by means of video laryngoscopy is that they become virtually useless when the camera view is obscured by bodily fluids, e.g., gastric contents and blood. IVOS Medical, LLC is a new medical device startup developing an economical, disposable and novel video laryngoscope sleeve for maintaining clear vision during breathing tube placement. The goal for our video laryngoscope apparatus is to elevate the current safety profile of intubation by decreasing aspiration risk and the time an individual goes without oxygen, while increasing intubation accuracy in patients who present with high risk of mortality. We believe our device will benefit first responders and healthcare providers throughout our nations’ medical centers in particular emergency departments, surgical suites and intensive care units. Preliminary testing in our Laerdal airway manikin with our prototype IVOS Medical BOSS G4, has shown significant improvement of visual acuity after clearing away simulated bodily fluids from the camera lens. Aims of this proposal are 1: Further development of 3D printed IVOS Medical BOSS Glide 4 (G4) video laryngoscope sleeve and compare speed and efficiency of successful intubation under aspiration conditions against the popular Verathon Glidescope AVL Blade 4, among 60 medical operators. 2: Perform Finite Element Analysis (FEA) of the BOSS G4 sleeve. 3: Develop and create 25 urethane injection molded samples of IVOS Medical Boss G4 laryngoscope sleeves. Phase II will focus on design based on end user feedback, additional testing including on human cadavers. Analysis of the suction capabilities to capture and remove potential airborne viral particles from the oropharyngeal space can be investigated at this time. Furthermore, additional physical and materials testing will be performed to reach the commercial-ready point at the end of Phase II. We believe that we can help save many lives affected everyday as well as increase the safety net for other medical professionals performing this life saving procedure.", "keywords": [ "3D Print", "Accident and Emergency department", "Affect", "Anatomy", "Aspirate substance", "Aspiration Pneumonia", "Blood", "Brain Injuries", "Breathing", "COVID-19 outbreak", "COVID-19 pandemic", "Cadaver", "Cessation of life", "Critical Illness", "Data", "Development", "Devices", "Distal", "Effectiveness", "Event", "Excision", "Feedback", "Finite Element Analysis", "Foundations", "Frequencies", "Gases", "Goals", "Health Personnel", "Heart Arrest", "Human", "Individual", "Injections", "Intensive Care Units", "Intratracheal Intubation", "Intubation", "Laryngoscopes", "Laryngoscopy", "Lead", "Life", "Liquid substance", "Manikins", "Manufacturer Name", "Materials Testing", "Medical", "Medical Device", "Medical center", "Methods", "Modeling", "Molds", "Monitor", "Mutation", "Operating Rooms", "Operative Surgical Procedures", "Oral cavity", "Oropharyngeal", "Oxygen", "Patients", "Phase", "Procedures", "Research", "Risk", "Safety", "Sampling", "Savings", "Specialist", "Speed", "Stomach", "Suction", "Testing", "Time", "Tube", "Urethane", "Viral", "Vision", "Visual Acuity", "Visualization", "Work", "base", "design", "first responder", "hemodynamics", "high risk", "lens", "mortality risk", "novel", "particle", "prevent", "prototype", "respiratory", "safety net", "symposium", "tool", "virtual", "vocal cord" ], "approved": true } }, { "type": "Grant", "id": "4096", "attributes": { "award_id": "1607069", "title": "2016 Cellular & Molecular Fungal Biology GRC, Plymouth, New Hampshire, June 19-24, 2016", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Biological Sciences (BIO)", "Symbiosis Infection & Immunity" ], "program_reference_codes": [], "program_officials": [ { "id": 13758, "first_name": "Michael", "last_name": "Mishkind", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2016-07-01", "end_date": "2017-06-30", "award_amount": 15000, "principal_investigator": { "id": 13759, "first_name": "Amy", "last_name": "Gladfelter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 226, "ror": "https://ror.org/05rad4t93", "name": "Gordon Research Conferences", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 226, "ror": "https://ror.org/05rad4t93", "name": "Gordon Research Conferences", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "This project will facilitate the attendance and participation of early career scientists in the Gordon Research Conference on Cellular and Molecular Fungal Biology to be held at the Holderness School, June 19-24, 2016. The goal of the conference is to disseminate information about fungal biology among an interdisciplinary group of researchers, and to increase our collective understanding of basic fungal biology and its application to socially important problems. Fungi are essential parts of the terrestrial nutrient cycle, play a central role in the development of biofuels, and produce many critically important chemicals. These diverse applications of fungi require the interdisciplinary acquisition and application of fundamental fungal biology. This project will support the convergence and exchange of new findings amongst an interdisciplinary group of scientists dedicated to the study of fungi. \n\nThe intellectual merit of the project is rooted in the meeting's highly interdisciplinary and interactive format. The meeting will feature topics that integrate multiple time and space scales for different questions in fungal biology to promote interactions amongst researchers with diverse perspectives within the community. There is a specific emphasis on integrating mathematical modeling and biophysics as a new addition to this meeting and an entire session is dedicated to the interface of fungal biology with the physical sciences. The meeting enables cross-fertilization of ideas, from cell biology to evolution, that occurs in and outside of the sessions and especially between junior and senior scientists. Young investigators emphasize from previous meetings how interactive the conference is and how responsive it is to the presentation of their work.\n\nThis conference has broad impacts on training and is dedicated to extending the research community by emphasizing women and members of underrepresented groups in inviting speakers. The current invited speakers are approximately 50% women, including several Latinas. The small size of the meeting and the emphasis on discussion (40% of meeting time is dedicated to discussions) encourages active participation. Poster sessions are featured without competing events to focus attention on the most junior scientists, who often have the newest data. The GRC on Cell and Molecular Fungal Biology also is dedicated to research that applies basic knowledge to socially important questions involving filamentous fungi, particularly mutualisms with plants (mycorrhizae), parasitism with plants (plant pathology) and animals (animal pathology), and industrial mycology (enzyme production). The interactions among researchers focused on both basic and socially important research speeds research aimed at solving societal problems caused by or that can be improved by fungi.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14336", "attributes": { "award_id": "2125941", "title": "Significant improvements in the development and application of olivine-melt thermometry and hygrometry: new experiments and analytical approaches", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Geosciences (GEO)", "Petrology and Geochemistry" ], "program_reference_codes": [], "program_officials": [ { "id": 6473, "first_name": "Jennifer", "last_name": "Wade", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-08-01", "end_date": null, "award_amount": 414716, "principal_investigator": { "id": 30928, "first_name": "Rebecca", "last_name": "Lange", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 169, "ror": "", "name": "Regents of the University of Michigan - Ann Arbor", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This award is funded in part under the American Rescue Plan Act of 2021 (Public Law 117-2).<br/><br/>Basaltic volcanism throughout Earth history has profoundly shaped the evolution of Earth’s crust and atmosphere, as well as the evolutionary path of life itself. In this study, erupted basalts are used as windows into the underlying mantle from which they were formed. The goal is to develop a new thermometer/hygrometer that enables both the temperature and water content of basalts to be readily and accurately obtained. Its ease of use will help generate large data sets, which will allow questions to be addressed about global differences in basalts erupted from diverse tectonic settings and throughout Earth history. The new thermometer/hygrometer will be made available to all interested users as a downloadable excel file. Two UM graduate students from diverse, under-represented backgrounds will work on this project. They will gain a broad range of skills, from expertise in conducting high-temperature and high-pressure experiments, performing thermodynamic calculations, and applying their results to better constrain mantle conditions that lead to partial melting. In addition, undergraduates from the M-STEM program at the University of Michigan (UM) will be recruited to work on this project.<br/><br/><br/>The goal of this project is to continue the experimental calibration a new olivine-melt thermometer that is based on the partitioning of Ni between olivine and basaltic liquids (DNiol/liq), and to further test whether it is independent of dissolved water at both crustal and mantle depths. Currently, the most widely used olivine-melt thermometers (based on DMgol/liq) are strongly dependent on water, and their application to hydrous basalts requires that melt H2O concentrations already be known, which is not always the case. With an H2O-independent thermometer in hand, based on DNiol/liq, it can be applied to olivine phenocrysts in hydrous basalts to obtain accurate temperatures, without prior knowledge of melt water contents. These temperatures can then be combined with Mg-based olivine-melt thermometers to obtain anhydrous temperatures and thus the magnitude of ∆T, the depression of the olivine liquidus due to dissolved water. Experiments will be performed to evaluate whether this depression of the olivine liquidus due to water is linearly and inversely correlated with the partitioning of Ca between olivine and melt (DCaol/liq), as indicated in preliminary work. To extend the calibration of this new olivine-melt thermometer/hygrometer, experiments will be performed on a variety of basaltic compositions over a range of water contents, temperatures, pressures (crustal and mantle) and fO2 conditions. Additionally, it is proposed to apply the new thermometer/hygrometer to a large number of natural basalts from a variety of tectonic settings. The results will shed light on the thermal/hydrous conditions in the mantle during partial melting across a variety of tectonic settings, from subduction zones to mantle plumes to continental rifts.<br/><br/>This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11520", "attributes": { "award_id": "5R21GM145980-02", "title": "Purification of Circular RNA by Ultrafiltration", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21614, "first_name": "MARY ANN ANN", "last_name": "WU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-06-01", "end_date": "2024-05-31", "award_amount": 179097, "principal_investigator": { "id": 22789, "first_name": "Scott M", "last_name": "Husson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 290, "ror": "https://ror.org/037s24f05", "name": "Clemson University", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 290, "ror": "https://ror.org/037s24f05", "name": "Clemson University", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "Circular RNA (circRNA) has important, understudied roles all across physiology and disease. Additionally, circularization of protein-coding RNA is a promising strategy for increasing the duration and quantity of therapeutic protein production and decreasing immunogenicity relative to linear messenger RNA (mRNA), such as those used to develop the first COVID-19 vaccines. Unfortunately, the synthesis of circRNA produces solutions that contain contaminating linear RNA precursors and nicked RNA that cause cellular immune responses; and no effective purification method has been demonstrated. The goal of this project is to test the feasibility of a novel concept to purify circular RNA with high purity and high yield. The proposed study has strong potential to advance biomedical research aimed at answering questions about the roles of circRNA in disease and biological function, where high sample purity is essential. It also has the potential to have a significant impact on the development of and access to circRNA therapies by demonstrating a high yield approach for their purification that does not exist today. Our research hypothesis is that membrane ultrafiltration can be used to separate RNA based on shape and size. We theorize that RNA transmission through ultrafiltration membranes will begin to occur at a critical flux (quotient of flowrate and membrane area) due to flow-induced elongation. Differences in elongational properties among RNA conformers will lead to differences in critical fluxes, which provides a basis for the purification of circRNA from linear RNA impurities. The Specific Aims are to (1) quantify ultrafiltration critical fluxes for circRNA, linear RNA precursor, and nicked RNA; (2) develop a protocol for purification of circRNA generated from self-splicing reactions, and (3) demonstrate protein production in cells for ultrafiltration-purified circRNA. In Aim 1, we will produce purified fractions of the different RNA conformers and accurately measure their transmission through ultrafiltration membranes to quantify their critical fluxes based on membrane properties. New technical knowledge generated using purified RNA conformers will identify flux conditions that can be used for the separation of circRNA from linear contaminants in self-splicing reaction solutions. In Aim 2, we will establish an easy to implement protocol that exploits differences in these critical fluxes to purify circRNA from self-splicing reaction solutions. This aim will advance knowledge on the key factors influencing circRNA purity and yield. In Aim 3, we will measure the quantity and evaluate the stability of protein production in cells for ultrafiltration-purified circRNA relative to circRNA purified using high-performance liquid chromatography, which represents the state-of-the-art approach. This project will provide a clear proof of concept for ultrafiltration-based purification of circRNA with high purity (95%) and high yield (>70%), which would be a significant advancement over the state of the art.", "keywords": [ "Address", "Adopted", "Area", "Biological Process", "Biology", "Biomedical Research", "COVID-19 prevention", "COVID-19 vaccine", "Cell Count", "Cells", "Code", "DNA", "Data", "Development", "Disease", "Emerging Communicable Diseases", "Flow Cytometry", "Goals", "Half-Life", "High Pressure Liquid Chromatography", "Hour", "Immune response", "Knowledge", "Measures", "Membrane", "Messenger RNA", "Methodology", "Methods", "Molecular Weight", "Output", "Pathology", "Performance", "Physiology", "Play", "Polymers", "Predisposition", "Production", "Property", "Proteins", "Protocols documentation", "RNA", "RNA Conformation", "RNA Precursors", "RNA Splicing", "RNA purification", "Reaction", "Recovery", "Research", "Resolution", "Role", "Sampling", "Shapes", "Structure", "Technology", "Therapeutic", "Transfection", "Ultrafiltration", "Vaccine Antigen", "Vaccine Production", "circular RNA", "conformer", "cytotoxicity", "experimental study", "feasibility testing", "immunogenicity", "in vivo", "innovation", "live cell imaging", "macromolecule", "novel", "novel strategies", "plasmid DNA", "prevent", "protein expression", "protein purification", "public health relevance", "theories", "therapeutic protein", "therapeutic vaccine", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "11264", "attributes": { "award_id": "2328095", "title": "CDS&E: Simulation- and Data-driven Peptide Antibody Design Targeting RBD and non-RBD Epitopes of SARS-CoV-2 Spike Protein", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "Cellular & Biochem Engineering" ], "program_reference_codes": [], "program_officials": [ { "id": 4079, "first_name": "Steven", "last_name": "Peretti", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-10-01", "end_date": "2025-09-30", "award_amount": 549351, "principal_investigator": { "id": 25373, "first_name": "Baofu", "last_name": "Qiao", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 630, "ror": "", "name": "CUNY Baruch College", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Drugs interact with proteins to disrupt bacterial and viral infections. Effective drugs are usually discovered rather than designed. Antibodies are protein complexes generated by the immune system to bind to and inactivate viruses. Peptides are short strings of amino acids that are being designed to mimic the protein binding activity of antibodies. Many aspects of protein-protein and protein-peptide interactions are not clearly understood. This project will apply an artificial intelligence approach to understand those interactions. The SARS-CoV-2 spike protein will be the model system for study. The resulting model for therapeutic peptide design will be provided to the research community on a variety of software platforms. The project will also support outreach to K-12 students regarding the SARS-CoV-2 virus and viral infections. \n\nThe overall objective is to develop a hybrid machine learning-simulation (MLSim) platform that allows us to better understand the molecular interaction between peptide drugs and viral proteins. The model viral protein system will be the SARS-CoV-2 spike proteins at both the receptor-binding domain (RBD) and the non-RBD. Transfer learning techniques for existing data models for protein-peptide interactions will be implemented. Online learning techniques will allow for the timely update of the predictive models with newly available data. The multiscale simulation component aids the machine learning part by supplying high-fidelity input data and cross-validating the predictions These efforts should result in molecular-level insight into viral protein-antibody interactions. There are two key outcomes anticipated from this project. First, a simulation- and data-enabled platform that integrates a high-throughput, customizable machine learning pipeline for fast screening and filtering peptide candidates, with high-fidelity all-atom explicit-solvent molecular dynamics simulation and free energy calculations. The second is fundamental insight into viral protein-peptide interactions and how those influence the design of neutralizing peptides.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8192", "attributes": { "award_id": "5R01AG071649-02", "title": "The economic and social impact of COVID-19 mitigation policies: A cross-country analysis of macro events", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8410, "first_name": "MINKI", "last_name": "CHATTERJI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-04-15", "end_date": "2026-01-31", "award_amount": 839609, "principal_investigator": { "id": 24033, "first_name": "Dean R", "last_name": "Lillard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 778, "ror": "", "name": "OHIO STATE UNIVERSITY", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 778, "ror": "", "name": "OHIO STATE UNIVERSITY", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The project, \"The economic and social impact of COVID-19 mitigation policies: A cross- country analysis of macro events,\" will explore the economic and social effects the mitigation policies and information environment that COVID-19 spawned. We will link those policies to data from ongoing household-based panel studies from 10 countries and rich administrative data from an eleventh. We will exploit the substantial intra and inter-country temporal and geographic variation in non-pharmacological intervention policies induced by the COVID-19 disease. That variation, coupled with pre-COVID baseline levels or long-running trends in the outcomes we will study, will identify the effects of the mitigation policies.", "keywords": [ "2019-nCoV", "Behavior", "COVID-19", "Case Fatality Rates", "Cessation of life", "Characteristics", "China", "Code", "Communities", "Coronavirus", "Country", "Coupled", "Data", "Demography", "Diagnosis", "Disease", "Economics", "Elderly", "Employment", "Environment", "Event", "Family member", "Federal Government", "Government", "Herd Immunity", "Heterogeneity", "Hospitalization", "Household", "Human", "Income", "Individual", "Industry", "Intervention", "Italy", "Life", "Link", "Local Government", "Medical", "Modeling", "Nature", "Occupations", "Outcome", "Pattern", "Personal Satisfaction", "Persons", "Policies", "Population", "Protocols documentation", "Records", "Research", "Research Personnel", "Resource Sharing", "Respondent", "Running", "SARS coronavirus", "SARS-CoV-2 infection", "Sampling", "Scientist", "Severe Acute Respiratory Syndrome", "Shock", "Social Impacts", "Sociology", "Surveys", "System", "Time", "Uncertainty", "Update", "Variant", "base", "coronavirus disease", "discount", "economic impact", "epidemiological model", "experience", "geographic difference", "member", "mortality", "outreach", "pandemic disease", "risk perception", "satisfaction", "social", "symposium", "transmission process", "trend" ], "approved": true } }, { "type": "Grant", "id": "10752", "attributes": { "award_id": "2235455", "title": "DREAM Sentinels: Selection of aptamers that target viral variants with high specificity", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "BIOSENS-Biosensing" ], "program_reference_codes": [], "program_officials": [ { "id": 961, "first_name": "Aleksandr", "last_name": "Simonian", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-01-01", "end_date": "2025-12-31", "award_amount": 640000, "principal_investigator": { "id": 1593, "first_name": "Hsin-Chih", "last_name": "Yeh", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 156, "ror": "", "name": "University of Texas at Austin", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 26813, "first_name": "Yi", "last_name": "Lu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 156, "ror": "", "name": "University of Texas at Austin", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "To combat infectious diseases, this project will develop a versatile platform that has a much shorter turn-around time in generating a new capture molecule that specifically binds a new viral variant with high affinity. The investigators will further convert the captured molecule into a sensor for virus detection, and also turn it into a blocking molecule to neutralize the virus. The current selection process is time-consuming and labor intensive. The goal of this project is to develop a streamlined process that can rapidly target emerging viral variants with high affinity and specificity. The proposed work will advance our knowledge in virus sensing and therapeutics, establishing a quick-responsive biosensing/actuating All-In-One platform that can be easily adapted to address future infectious diseases. To increase impact, the investigators will work with local K-12 students in several outreach programs, with the goal of training the students to develop novel tools and encouraging them into a career path in science, technology, engineering and mathematics.\n\nDevelopment of aptamer sensors and therapeutics is hampered by the bottleneck in the workflow of current gold standard SELEX (systematic evolution of ligands by exponential enrichment), especially the counterselection process, which aims to eliminate the candidates that bind structurally similar relatives of the target. While the counterselection is key to selecting highly specific aptamers against a specific target, it is a time-consuming, labor-intensive process that often fails. To address this issue, this project will combine SELEX workflow with a complementary high-throughput chip selection approach that can fully characterize the binding affinity, kinetics and specificity of each aptamer variant in the library against a number of structurally similar viral targets. This total-analysis approach not only bypasses the need to perform counterselections but also allows selection of aptamers that can differentiate structurally similar viral targets. The virus-binding aptamers will then be integrated with novel fluorogenic aptamer design to create new sensors that light up upon binding the target viruses and can be turned into virus inhibitors that bind and block the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein from interacting with the angiotensin-converting enzyme 2 (ACE2) receptors on human host cells. The proposed research thus has both biosensing and bioactuation components that address new biological threats.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6912", "attributes": { "award_id": "1IK2RX003546-01A2", "title": "Enhanced Home-Based Exercise Therapy for Peripheral Arterial Disease through Mobile Health and Remote Monitoring", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 22750, "first_name": "Arash", "last_name": "Harzand", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1477, "ror": "https://ror.org/05eq41471", "name": "Veterans Health Administration", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "An estimated 8.5 million Americans (or 7% of US adults) and nearly 10% of veterans are estimated to have peripheral arterial disease (PAD). Significantly debilitating and negatively impacting quality of life, the primary symptom of PAD is claudication (reproducible leg pain with ambulation) that leads to impaired mobility, loss of functional independence, and a heightened risk for amputation. Veterans are at an increased risk of developing symptomatic PAD due to their disproportionately high rates of PAD risk factors such as diabetes, smoking, and hypertension, the most prominent PAD risk factors. Supervised exercise therapy is proven to decrease claudication and enhance mobility in PAD; however, fewer than 25% of eligible patients enroll. Participation in this facility-based program requires travel to a rehabilitation center 3 times per week for 12-weeks, which can be burdensome and costly for Veterans, many of whom live in rural areas and on fixed incomes. There is, therefore, a need to develop a convenient and effective alternative exercise rehabilitation program for Veterans with PAD, particularly in light of safety considerations now associated with this population’s travel to group facilities in the current COVID pandemic. A promising approach to increase access to exercise rehabilitation for PAD is remote, home-based exercise therapy (HBET). Our group has successfully delivered a smartphone-enabled HBET program to Veterans with coronary artery disease with a 3-fold increase in participation and high satisfaction (80%). To this end, we are committed to utilizing technology innovations to implement HBET for Veterans with PAD successfully. HBET programs combine self-led walking exercises with health coaching and exercise tracking with a wearable activity monitor. Adapting HBET to PAD is difficult, however, due to the added complexity of an exercise prescription that requires the patient to walk until they experience near-maximal leg pain. Even with active coaching, successfully implementing HBET for PAD with long-term adherence has been difficult in the past. Our goal, therefore, is to leverage newer mobile health (mHealth) tools to adapt HBET for PAD. We propose to test our technology-enhanced approach for HBET by partnering with a successful VA lifestyle program, MOVE!, which has demonstrated success in achieving sustained weight loss and reduced diabetes onset through lifestyle modification. As increased physical activity is a core element of MOVE!, participation may help increase adherence with HBET for PAD. Our newly proposed program, Smart MOVE!, will be a multi-component program featuring a tailored version of MOVE! and a novel mHealth device called the LifeQ to improve convenience, access, and adherence to HBET for PAD. Aim 1 (Years 1-2): Identify barriers and facilitators to MOVE! participation among Veterans with PAD. Aim 2 (Years 1-2): Evaluate the feasibility of the LifeQ device to monitor exercise during HBET Aim 3 (Years 2-5): Determine the feasibility of proceeding with Smart MOVE! through a pilot randomized trial. As a VA physician actively treating Veterans with PAD, I have seen first-hand the challenges they face in accessing guideline-directed treatments such as supervised exercise. This study will lay the groundwork and provide evidence to proceed with Smart MOVE!, a much-needed patient-centered exercise rehabilitation program for PAD. Additionally, the proposed training plan will support my progress towards becoming an independent VA rehabilitation clinician-scientist focused on improving care quality and treatment outcomes for Veterans with PAD.", "keywords": [ "Accelerometer", "Activities of Daily Living", "Adherence", "Adult", "Affect", "American", "Amputation", "Behavioral", "Body Weight decreased", "COVID-19 pandemic", "Cardiac rehabilitation", "Cellular Phone", "Clinical", "Complex", "Coronary Arteriosclerosis", "Data", "Devices", "Diabetes Mellitus", "Elements", "Enhancement Technology", "Enrollment", "Exercise", "Exercise Therapy", "Face", "Goals", "Gold", "Guidelines", "Health", "Health Technology", "Home", "Hospitals", "Hypertension", "Impairment", "Income", "Indirect Calorimetry", "Intervention", "Interview", "Leadership", "Leg", "Life Style", "Life Style Modification", "Light", "Measurement", "Monitor", "Myocardial Infarction", "Oxygen Consumption", "Pain in lower limb", "Patient Education", "Patients", "Peripheral arterial disease", "Physical activity", "Physicians", "Population", "Provider", "Quality of Care", "Quality of life", "Rehabilitation Centers", "Rehabilitation therapy", "Reproducibility", "Resolution", "Risk", "Risk Factors", "Safety", "Scientist", "Smoking", "Stroke", "Structure", "Supervision", "Symptoms", "Technology", "Testing", "Time", "Training", "Travel", "Treatment outcome", "Vertebral column", "Veterans", "Walking", "aged", "base", "behavior change", "claudication", "cost", "design", "evidence base", "exercise prescription", "exercise program", "exercise regimen", "exercise rehabilitation", "experience", "functional independence", "functional loss", "functional outcomes", "high risk", "improved", "improved mobility", "informant", "innovation", "mHealth", "mortality risk", "multi-component intervention", "novel", "patient oriented", "primary outcome", "programs", "randomized trial", "remote monitoring", "rural area", "satisfaction", "success", "symptomatic improvement", "tool" ], "approved": true } } ], "meta": { "pagination": { "page": 6, "pages": 1442, "count": 14420 } } }